J Korean Med Sci.  2024 Oct;39(41):e323. 10.3346/jkms.2024.39.e323.

Letter to the Editor: Commentary on “Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma”

• Tini P

• KMID: 2560599
• DOI: http://doi.org/10.3346/jkms.2024.39.e323

Reference

1. Lee Y, Lee E, Roh TH, Kim SH. Bevacizumab alone versus bevacizumab plus irinotecan in patients with recurrent glioblastoma: a nationwide population-based study. J Korean Med Sci. 2024; 39(34):e244. PMID: 39228184.

2. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733–4740. PMID: 19720927.

3. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci. 2012; 19(12):1636–1640. PMID: 23047061.

4. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943–953. PMID: 25035291.

5. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017; 377(20):1954–1963. PMID: 29141164.

6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997–1003. PMID: 15758010.

7. Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, et al. A randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma. Oncologist. 2019; 24(4):521–528. PMID: 30266892.

8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722–4729. PMID: 17947719.

9. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709–722. PMID: 24552318.